Aino Health (AINO) Q1 2026 earnings summary

Executive summary

• Q1 2026 marked a strategic shift toward a more scalable SaaS business, with a focus on recurring revenue and operational scalability.

• Net sales declined to KSEK 5,531 from KSEK 7,378 year-over-year, reflecting discontinued unprofitable customer relationships and reduced consulting revenue.

• Majority of revenue now comes from recurring SaaS subscriptions, with 116,000 subscribers at quarter-end.

• Investments continued in quality and information security frameworks, including ISO 27001 and ISO 9001 audits.

• Strategic partnership formed with UK-based Salubrium and Patient Advocate to expand workforce wellbeing solutions.

Financial highlights

• Net sales for Q1 2026 were KSEK 5,531, down from KSEK 7,378 in Q1 2025.

• Operating loss (EBIT) was KSEK -2,022, compared to KSEK -420 in the prior year.

• Loss after financial items was KSEK -2,213, versus KSEK -554 year-over-year.

• Cash flow from operating activities was KSEK -2,144, compared to KSEK 504 in Q1 2025.

• Cash and bank balances at quarter-end were KSEK 3,814.

Outlook and guidance

• Management remains confident in long-term market opportunities for data-driven work ability management.

• Focus remains on growing SaaS revenue, operational scalability, and disciplined execution to return to growth in 2026.